Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Drug-Linker Conjugates for ADC
    (10)
  • Topoisomerase
    (4)
  • ADC Cytotoxin
    (1)
  • Antibody-Drug Conjugates (ADCs)
    (1)
  • Apoptosis
    (1)
  • Autophagy
    (1)
  • Chk
    (1)
  • DNA/RNA Synthesis
    (1)
  • EGFR
    (1)
  • Others
    (4)
Filter
Search Result
Results for "

sn38

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    23
    TargetMol | Inhibitors_Agonists
  • Inhibitory Antibodies
    1
    TargetMol | Inhibitory_Antibodies
  • PROTAC Products
    3
    TargetMol | PROTAC
  • Natural Products
    1
    TargetMol | Natural_Products
  • Antibody Products
    1
    TargetMol | Antibody_Products
SN-38
SN 38, NK012
T170386639-52-3
SN-38 (NK012) is the active metabolite of Irinotecan, a DNA topoisomerase I (Topo I) inhibitor, which inhibits DNA and RNA synthesis (IC50=0.077 1.3 μM). SN-38 has antitumor activity and induces autophagy.
  • Inquiry Price
Size
QTY
MC-VC-PAB-DMEA-SN38
MC-Val-Cit-PAB-DMEA-SN38
T205753
MC-VC-PAB-DMEA-SN38 is a thiol-reactive Drug-linker, featuring an innovative highly stable and degradable linker. SN-38 can inhibit the synthesis of DNA and RNA, and is commonly used in the synthesis of antibody-drug conjugates (ADC).
  • Inquiry Price
Size
QTY
NH2-PEG4-VC-PAB-DMEA-SN38
T205808
NH2-PEG4-VC-PAB-DMEA-SN38 is a transpeptidase reaction-type Drug-linker with an innovative highly stable and degradable linker. SN38 can inhibit the synthesis of DNA and RNA, and can be used in the synthesis of antibody-drug conjugates (ADCs).
  • Inquiry Price
Size
QTY
CL2-MMT-SN38
CL2-MMT-SN38
T384741084888-82-3
CL2-MMT-SN38 is a derivative of SN-38, which is a potent anticancer agent and the active metabolite of Irinotecan (CPT-11), a Topoisomerase I inhibitor.
  • Inquiry Price
Size
QTY
MC-SN38
MC-SN38
T389621473403-87-0
MC-SN38 is a drug-linker conjugate that pairs the potent microtubule-disrupting agent SN38 with a non-cleavable MC linker, designed for use in antibody drug conjugates (ADCs). SN38, the active metabolite of the Topoisomerase I inhibitor Irinotecan, works by inhibiting DNA synthesis and inducing DNA single-strand breaks.
  • Inquiry Price
Size
QTY
Mc-VC-PAB-SN38
Mc-VC-PAB-SN38
T392221801838-28-7
Mc-VC-PAB-SN38 consists of a cleavable ADC linker (Mc-VC-PAB) and SN38, which is part of an antibody-coupled reactive molecule commonly used to synthesize antibody-coupled reactive molecules (ADCs) that target sites of action.
  • Inquiry Price
Size
QTY
SN38-COOH
T778822170118-23-5
SN38-COOH, the active metabolite of the topoisomerase I inhibitor irinotecan, is utilized in the synthesis of antibody-drug conjugates (ADCs). It functions by inhibiting DNA and RNA synthesis [1] [2].
  • Inquiry Price
8-10 weeks
Size
QTY
SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3
T811431373170-36-5
SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a drug-linker conjugate for antibody-drug conjugates (ADCs), consisting of the anti-cancer agent SN38 linked to Lys(MMT)-PAB-oxydiacetamide-PEG8-N3. It serves as a click chemistry reagent featuring an azide group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAC) with alkyne-bearing molecules and can also engage in strain-promoted alkyne-azide cycloaddition (SPAAC) with compounds containing DBCO or BCN groups, facilitating the synthesis of ADCs [1].
  • Inquiry Price
8-10 weeks
Size
QTY
Mal-va-mac-SN38
T893772778229-31-3
Mal-va-mac-SN38 is a conjugate molecule functioning as an ADC (Antibody-Drug Conjugate) drug-linker. This compound comprises the cytotoxic ADC agent SN-38 and a linker. Once inside the body, Mal-va-mac-SN38 rapidly forms a covalent bond with endogenous albumin, resulting in the formation of HSA-va-mac-SN38. It demonstrates remarkable stability in human plasma and exhibits both antitumor and antimetastatic properties.
  • Inquiry Price
Size
QTY
CL2E-SN38 TFA
T77837
CL2E-SN-38 TFA, a structurally stable and highly releasable antibody drug conjugate (ADC), comprises SN-38, the active metabolite of Irinotecan derived from camptothecins, known for its Topoisomerase I inhibitory activity [1].
  • Inquiry Price
Size
QTY
CL2E-SN38
T827101639139-65-3
CL2E-SN-38 is a structurally stable and highly releasable antibody-drug conjugate (ADC) incorporating SN-38, the active metabolite of Irinotecan and a potent Topoisomerase I inhibitor [1] from the camptothecins class.
  • Inquiry Price
8-10 weeks
Size
QTY
CL2A-SN-38
CL2A-SN38, CL2A SN 38
T177311279680-68-0
CL2A-SN-38 consists of a CL2A linker and an anticancer compound, SN-38, which delivers active molecules within tumor cells and in the tumor microenvironment, often in conjunction with antibodies to make biologically active antibody-coupled reactive molecules (ADCs).
  • Inquiry Price
7-10 days
Size
QTY
TP3011
CH0793011
T13191534605-74-8
TP3011 is a potent topoisomerase I inhibitor equipotent as SN38 and is an active metabolite of CH-0793076.
  • Inquiry Price
3-6 months
Size
QTY
MAC glucuronide phenol-linked SN-38
T185382246380-69-6
MAC glucuronide phenol-linked SN-38, a pH-sensitive lactone and DNA topoisomerase I inhibitor drug linker, exhibits cytotoxicity in L540cy and Ramos cells, with IC50 values of 113 ng mL and 67 ng mL, respectively[1].
  • Inquiry Price
Size
QTY
MAC glucuronide α-hydroxy lactone-linked SN-38
T187222246380-70-9
MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a cytotoxic drug linker that maintains a stabilized lactone form, demonstrating efficacy against L540cy and Ramos cells with IC50 values of 99 and 105 ng mL, respectively[1].
  • Inquiry Price
Size
QTY
CLM3
T2000801312024-59-1
CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.
  • Inquiry Price
6-8 weeks
Size
QTY
DTS-108
T203287951792-83-9
DTS-108 is a prodrug of SN38 (a topoisomerase I inhibitor). It is a conjugate formed by linking SN38 to a human oligopeptide through an esterase-sensitive crosslinker. DTS-108 exhibits anticancer activity against colorectal cancer, lung cancer, and breast cancer.
  • Inquiry Price
Size
QTY
SAR-020106
T213311184843-57-9
SAR-020106 is a potent, ATP-competitive, and selective CHK1 inhibitor with an IC50 of 13.3 nmol L on the isolated human enzyme.
  • Inquiry Price
Size
QTY
Labetuzumab govitecan
Labetuzumab-SN38, IMMU-130, IMMU130, IMMU 130, hMN14-SN38
T255931469876-18-3
Labetuzumab govitecan is an anti-CEACAM5 SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.
  • Inquiry Price
Size
QTY
Ki23057
T69162516523-31-2
Ki23057 is a a FGFR2 inhibitor, which enhances the chemosensitivity of drug-resistant gastric cancer cell lines when used in combination with chemotherapeutic drugs. Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16. The apoptosis process might be the main mechanism underlying the synergistic effect of these combinations. The ERCC1 and p53 genes may play an integral role in the synergism between Ki23057 and chemotherapeutic agents in drug-resistant cell lines. (source: Cancer Lett. 2011 Aug 1;307(1):47-52).
  • Inquiry Price
6-8 weeks
Size
QTY
ZBH-1205
T703801613587-62-4
ZBH-1205 is a novel camptothecin derivative, revealing potent antitumor activities mainly through cell apoptosis pathway, being more effective than cpt-11 and sn38 at inhibiting topoismerase-1
  • Inquiry Price
10-14 weeks
Size
QTY
Antitumor agent-102
T79263
Antitumor Agent-102 (Compound 10), a conjugate integrating a Topoisomerase I inhibitor SN38 with a glucose transporter inhibitor, specifically targets colorectal cancer. This agent facilitates elevated levels of free SN38 in tumor tissues compared to Irinotecan [1].
  • Inquiry Price
Size
QTY
12-Ethyl-9-hydroxycamptothecin
7-Ethyl-10-Hydroxy-Camptothecin
TN2460119577-28-5
12-Ethyl-9-hydroxycamptothecin (SN38) is the active metabolite of irinotecan, a topoisomerase I inhibitor, with potential anticancer activity for use in the study of colon and rectal cancer.
  • Inquiry Price
7-10 days
Size
QTY